Recovery Versus Persistence of Disordered Mineral Metabolism in Kidney Transplant Recipients

Seminars in Nephrology

Volumn 33, Issue 2, 2013, Pages 191-203

  Evenepoel, Pieter ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Bone disease; Hyperparathyroidism; Mineral metabolism; Renal transplantation

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIMIMETIC AGENT; CALCITONIN; CALCITRIOL; CALCIUM; CINACALCET; CYCLOSPORIN; DENOSUMAB; FIBROBLAST GROWTH FACTOR 23; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PHOSPHATE; PLACEBO; RAPAMYCIN; ROMOSOZUMAB; TACROLIMUS; VITAMIN D;

ARTICLE; BLOOD VESSEL CALCIFICATION; BONE DENSITY; BONE DISEASE; CHRONIC KIDNEY DISEASE; DIALYSIS; DRUG EFFICACY; DRUG SAFETY; FRACTURE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPOPHOSPHATEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CALCIFICATION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; METABOLIC DISORDER; MINERAL METABOLISM; MORBIDITY; MORTALITY; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PARATHYROIDECTOMY; PATHOGENESIS; PHENOTYPE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; SINGLE DRUG DOSE; SURVIVAL;

BONE DISEASES, METABOLIC; GRAFT SURVIVAL; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM, SECONDARY; HYPOPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; NEPHROCALCINOSIS; RECOVERY OF FUNCTION; TREATMENT OUTCOME; VASCULAR CALCIFICATION;

EID: 84875273664     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2012.12.019     Document Type: Article

References (137)

1. Isakova T., Wahl P., Vargas G.S., Gutierrez O.M., Scialla J., Xie H., et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011, 79:1370-1378.
2. Moe S., Drueke T., Cunningham J., Goodman W., Martin K., Olgaard K., et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006, 69:1945-1953.
3. Wolfe R.A., Ashby V.B., Milford E.L., Ojo A.O., Ettenger R.E., Agodoa L.Y.C., et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999, 341:1725-1730.
4. Bonarek H., Merville P., Bonarek M., Moreau K., Morel D., Aparicio M., et al. Reduced parathyroid functional mass after successful kidney transplantation. Kidney Int 1999, 56:642-649.
5. Parfitt A. Hypercalcemic hyperparathyroidism following renal transplantation: differential diagnosis, management, and implications for cell population control in the parathyroid gland. Miner Electrolyte Metab 1982, 8:92-112.
6. Evenepoel P., Claes K., Kuypers D., Maes B., Bammens B., Vanrenterghem Y. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant 2004, 19:1281-1287.
7. Castleman B., Kibbee B.U. Case records of the Massachusetts General Hospital: case 46-1963. N Engl J Med 1963, 269:97-101.
8. Evenepoel P., Sprangers B., Lerut E., Bammens B., Claes K., Kuypers D., et al. Mineral metabolism in renal transplant recipients discontinuing cinacalcet at the time of transplantation: a prospective observational study. Clin Transplant 2012, 26:393-402.
9. Triponez H., Clark O.H., Vanrenterghem Y., Evenepoel P. Surgical treatment of persistent hyperparathyroidism after transplantation. Ann Surg 2008, 248:18-30.
10. Evenepoel P., Naesens M., Claes K., Kuypers D., Vanrenterghem Y. Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant 2007, 7:1193-1200.
11. Evenepoel P., Meijers B.K.I., De jonge H., Naesens M., Bammens B., Claes K., et al. Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol 2008, 3:1829-1836.
12. Bhan I., Shah A., Holmes J., Isakova T., Gutierrez O., Burnett S.-A., et al. Post-transplant hypophosphatemia: tertiary 'hyper-phosphatoninism'?. Kidney Int 2006, 70:1486-1494.
13. Wissing K.M., Broeders N., Moreno-Reyers R., Gervy C., Stallenberg B., Abramowicz D. A controlled study of vitamin D3 to prevent bone loss in renal-transplant patients receiving low doses of steroids. Transplantation 2005, 79:108-115.
14. Courbebaisse M., Thervet E., Souberbielle J.C., Zuber J., Eladari D., Martinez F., et al. Effects of vitamin D supplementation on the calcium-phosphate balance in renal transplant patients. Kidney Int 2009, 75:646-651.
15. de Sevaux R.G.L., Hoitsma A.J., Corstens F.H.M., Wetzels J.F.M. Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study. J Am Soc Nephrol 2002, 13:1608-1614.
16. Helvig C.F., Cuerrier D., Hosfield C.M., Ireland B., Kharebov A.Z., Kim J.W., et al. Dysregulation of renal vitamin D metabolism in the uremic rat. Kidney Int 2010, 78:463-472.
17. Ewers B., Gasbjerg A., Moelgaard C., Frederiksen A.M., Marckmann P. Vitamin D status in kidney transplant patients: need for intensified routine supplementation. Am J Clin Nutr 2008, 87:431-437.
18. Stavroulopoulos A., Cassidy M.J.D., Porter C.J., Hosking D.J., Roe S.D. Vitamin D status in renal transplant recipients. Am J Transplant 2007, 7:2546-2552.
19. Maxmen A. Nutrition advice: the vitamin D-lemma. Nature 2011, 475:23-25.
20. Evenepoel P., Van Den Bergh B., Naesens M., de Jonge H., Bammens B., Claes K., et al. Calcium metabolism in the early posttransplantation period. Clin J Am Soc Nephrol 2009, 4:665-672.
21. Reinhardt W., Bartelworth H., Jockenhövel F., Schmidt-Gayk H., Witzke O., Wagner K., et al. Sequential changes of biochemical bone parameters after kidney transplantation. Nephrol Dial Transplant 1998, 13:436-442.
22. Cundy T., Kanis J.A., Heynen G., Morris P.J., Oliver D.O. Calcium metabolism and hyperparathyroidism after renal transplantation. QJM 1983, 52:67-78.
23. Schwartz G.H., David D.S., Riggio R.R., Saville P.D., Whitsell J.C., Stenzel K.H., et al. Hypercalcemia after renal transplantation. Am J Med 1970, 49:42-51.
24. Vezzoli G., Elli A., Palazzi P., Bertoni T., Scabini M., Quarto di Palo F., et al. High plasma ionized calcium with normal PTH and total calcium levels in normal-function kidney transplant recipients. Nephron 1986, 42:290-294.
25. Evenepoel P., Bammens B., Claes K., Kuypers D., Meijers B.K., Vanrenterghem Y. Measuring total blood calcium displays a low sensitivity for the diagnosis of hypercalcemia in incident renal transplant recipients. Clin J Am Soc Nephrol 2010, 5:2085-2092.
26. Pande S., Ritter C.S., Rothstein M., Wiesen K., Vassiliadis J., Kumar R., et al. FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. Nephron Physiol 2006, 104:23-32.
27. Trombetti A., Richert L., Hadaya K., Graf J.D., Herrmann F.R., Ferrari S.L., et al. Early post-transplantation hypophosphatemia is associated with elevated FGF-23 levels. Eur J Endocrinol 2011, 164:839-847.
28. Bacic D., Wagn C.A., Kaissling B., Biber J., Murer H. Novel aspects in regulated expression of the renal type IIa Na/Pi-cotransporter. Kidney Int 2004, 91:5-12.
29. Sirilak S., Chatsrisak K., Ingsathit A., Kantachuvesiri S., Sumethkul V., Stitchantrakul W., et al. Renal phosphate loss in long-term kidney transplantation. Clin J Am Soc Nephrol 2012, 7:323-331.
30. Lehmann G., Ott U., Stein G., Steiner T., Wolf G. Renal osteodystrophy after successful renal transplantation: a histomorphometric analysis in 57 patients. Transplant Proc 2007, 39:3153-3158.
31. Abdallah K.A., Jorgetti V., Pereira R.C., Reis L.M., Pereira L.M., Correa P.H., et al. Improvement of adynamic bone disease after renal transplantation. Braz J Med Biol Res 2006, 39:31-41.
32. Carlini R.G., Rojas E., Weisinger J.R., Lopez M., Martinis R., Arminio A., et al. Bone disease in patients with long-term renal transplantation and normal renal function. Am J Kidney Dis 2000, 36:160-166.
33. Montalban C., de Francisco A.L.M., Marinosa M.L., Zubimendi J.A., Unzueta M.G., Amado J.A., et al. Bone disease in long-term adult kidney transplant patients with normal renal function. Kidney Int 2003, 63:129-132.
34. Borchhardt K.A., Sulzbacher I., Benesch T., Födinger M., Sunder-Plassmann G., Haas M. Low-turnover bone disease in hypercalcemic hyperparathyroidism after kidney transplantation. Am J Transplant 2007, 7:2515-2521.
35. Faugere M.-C., Mawad H., Qi Q., Friedler R., Malluche H.H. High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol 2000, 11:1093-1099.
36. Rojas E., Carlini R.G., Clesca P., Arminio A., Suniaga O., De Elguezabal K., et al. The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodeling. Kidney Int 2003, 63:1915-1923.
37. Coco M., Glicklich D., Faugere M.C., Burris L., Bognar I., Durkin P., et al. Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 2003, 14:2669-2676.
38. Julian B., Laskow D., Dobovsky E., Curtis J., Quarles L.D. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 1991, 325:544-550.
39. Cruz E.A.S., Lugon J.R., Jorgetti V., Draibe S.A., Carvalho A.B. Histologic evolution of bone disease 6 months after successful kidney transplantation. Am J Kidney Dis 2004, 44:747-756.
40. Martins L., Queiros J., Ferreira A., Henriques A.C., Sarmento A.M., Pereira M.C., et al. Renal osteodystrophy: histologic evaluation after renal transplantation. Transplant Proc 2000, 32:2599-2601.
41. Parker C.R., Freemont A.J., Blackwell P.J., Grainge M.J., Hosking D.J. Cross-sectional analysis of renal transplantation osteoporosis. J Bone Miner Res 1999, 14:1943-1951.
42. Heaf J.G. Bone disease after renal transplantation. Transplantation 2003, 75:315-325.
43. Pichette V., Bonnardeaux A., Prudhomme L., Gagné M., Cardinal J., Ouimet D. Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study. Am J Kidney Dis 1996, 28:105-114.
44. Marcen R., Caballero C., Pascual J., Teruel J.L., Tenorio M., Ocana J., et al. Lumbar bone mineral density in renal transplant patients on neoral and tacrolimus: a four-year prospective study. Transplantation 2006, 81:826-831.
45. Brandenburg V.M., Politt D., Ketteler M., Fassbender W.J., Heussen N., Westenfeld R., et al. Early rapid loss followed by long-term consolidation characterizes the development of lumbar bone mineral density after kidney transplantation. Transplantation 2004, 77:1566-1571.
46. Kanaan N., Claes K., Devogelaer J.P., Vanderschueren D., Depresseux G., Goffin E., et al. Fibroblast growth factor-23 and parathyroid hormone are associated with post-transplant bone mineral density loss. Clin J Am Soc Nephrol 2010, 5:1887-1892.
47. Ing S.W., Sinnott L.T., Donepudi S., Davies E.A., Pelletier R.P., Lane N.E. Change in bone mineral density at one year following glucocorticoid withdrawal in kidney transplant recipients. Clin Transplant 2011, 25:E113-E123.
48. Casez J.P., Lippuner K., Horber F.F., Montandon A., Jaeger P. Changes in bone mineral density over 18 months following kidney transplantation: the respective roles of prednisone and parathyroid hormone. Nephrol Dial Transplant 2002, 17:1318-1326.
49. Kunzendorf U., Kramer B.K., Arns W., Braun J., Grossmann J., Pietruck F., et al. Bone disease after renal transplantation. Nephrol Dial Transplant 2008, 23:450-458.
50. Hamdy N.A., Kanis J.A., Beneton M.N., Juttmann J.R., Jordans J.G., Josse S., et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. Br Med J 1995, 310:358-363.
51. Coen G., Ballanti P., Bonucci E., Calabria S., Costantini S., Ferrannini M., et al. Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH. Nephron 2002, 91:103-111.
52. Malluche H.H., Mawad H.W., Monier-Faugere M.C. Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res 2011, 26:1368-1376.
53. Malluche H.H., Mawad H., Monier-Faugere M.C. The importance of bone health in end-stage renal disease: out of the frying pan, into the fire?. Nephrol Dial Transplant 2004, 19(Suppl 1):i9-i13.
54. Malluche H.H., Monier-Faugere M.C., Herberth J. Bone disease after renal transplantation. Nat Rev Nephrol 2010, 6:32-40.
55. Canalis E., Delany A.M. Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci 2002, 966:73-81.
56. Hahn T.J., Halstead L.R., Baran D.T. Effects off short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man. J Clin Endocrinol Metab 1981, 52:111-115.
57. Daoussis D., Andonopoulos A.P. The emerging role of Dickkopf-1 in bone biology: is it the main switch controlling bone and joint remodeling?. Semin Arthritis Rheum 2011, 41:170-177.
58. Yao W., Cheng Z., Pham A., Busse C., Zimmermann E.A., Ritchie R.O., et al. Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization. Arthritis Rheum 2008, 58:3485-3497.
59. Westenfeld R., Schlieper G., Woltje M., Gawlik A., Brandenburg V., Rutkowski P., et al. Impact of sirolimus, tacrolimus and mycophenolate mofetil on osteoclastogenesis-implications for post-transplantation bone disease. Nephrol Dial Transplant 2011, 26:4115-4123.
60. Campistol J.M., Holt D.W., Epstein S., Gioud-Paquet M., Rutault K., Burke J.T. Bone metabolism in renal transplant patients treated with cyclosporine or sirolimus. Transpl Int 2005, 18:1028-1035.
61. Schwarz C., Benesch T., Kodras K., Oberbauer R., Haas M. Complete renal tubular acidosis late after kidney transplantation. Nephrol Dial Transplant 2006, 21:2615-2620.
62. Tataranni T., Biondi G., Cariello M., Mangino M., Colucci G., Rutigliano M., et al. Rapamycin-induced hypophosphatemia and insulin resistance are associated with mTORC2 activation and klotho expression. Am J Transplant 2011, 11:1656-1664.
63. Navaneethan S.D., Sankarasubbaiyan S., Gross M.D., Jeevanantham V., Monk R.D. Tacrolimus-associated hypomagnesemia in renal transplant recipients. Transplant Proc 2006, 38:1320-1322.
64. Jilka R.L., Weinstein R.S., Bellido T., Roberson P., Parfitt A.M., Manolagas S.C. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999, 104:439-446.
65. Cejka D., Herberth J., Branscum A.J., Fardo D.W., Monier-Faugere M.C., Diarra D., et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol 2011, 6:877-882.
66. Costa A.G., Cremers S., Rubin M.R., McMahon D.J., Sliney J., Lazaretti-Castro M., et al. Circulating sclerostin in disorders of parathyroid gland function. J Clin Endocrinol Metab 2011, 96:3804-3810.
67. Wijenayaka A.R., Kogawa M., Lim H.P., Bonewald L.F., Findlay D.M., Atkins G.J. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One 2011, 6:e25900.
68. Coen G., Mazzaferro S., Ballanti P., Sardella D., Chicca S., Manni M., et al. Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: a cross-sectional study. Nephrol Dial Transplant 1996, 11:813-819.
69. Viaene L., Meijers B.K., Vanrenterghem Y., Evenepoel P. Evidence in favor of a severely impaired net intestinal calcium absorption in patients with (early-stage) chronic kidney disease. Am J Nephrol 2012, 35:434-441.
70. Spiegel D.M., Brady K. Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets. Kidney Int 2012, 81:1116-1122.
71. Yu R.W., Faull R.J., Coates P.T., Coates P.S. Calcium supplements lower bone resorption after renal transplant. Clin Transplant 2012, 26:292-299.
72. Nguyen P.T., Coche E., Goffin E., Beguin C., Vlassenbroek A., Devuyst O., et al. Prevalence and determinants of coronary and aortic calcifications assessed by chest CT in renal transplant recipients. Am J Nephrol 2007, 27:329-335.
73. Hernandez D., Rufino M., Bartolomei S., Gonzalez-Rinne A., Lorenzo V., Cobo M., et al. Clinical impact of preexisting vascular calcifications on mortality after renal transplantation. Kidney Int 2005, 67:2015-2020.
74. Abedi S.A., Tarzamni M.K., Nakhjavani M.R., Bohlooli A. Effect of renal transplantation on coronary artery calcification in hemodialysis patients. Transplant Proc 2009, 41:2829-2831.
75. Moe S.M., O'Neill K.D., Resterova M., Fineberg N., Persohn S., Meyer C.A. Natural history of vascular calcification in dialysis and transplant patients. Nephrol Dial Transplant 2004, 19:2387-2393.
76. Mazzaferro S., Pasquali M., Taggi F., Baldinelli M., Conte C., Muci M.L., et al. Progression of coronary artery calcification in renal transplantation and the role of secondary hyperparathyroidism and inflammation. Clin J Am Soc Nephrol 2009, 4:685-690.
77. Seyahi N., Cebi D., Altiparmak M.R., Akman C., Ataman R., Pekmezci S., et al. Progression of coronary artery calcification in renal transplant recipients. Nephrol Dial Transplant 2012, 27:2101-2107.
78. Oschatz E., Benesch T., Kodras K., Hoffmann U., Haas M. Changes of coronary calcification after kidney transplantation. Am J Kidney Dis 2006, 48:307-313.
79. Schankel K., Robinson J., Bloom R.D., Guerra C., Rader D., Joffe M., et al. Determinants of coronary artery calcification progression in renal transplant recipients. Am J Transplant 2007, 7:2158-2164.
80. Marechal C., Coche E., Goffin E., Dragean A., Schlieper G., Nguyen P., et al. Progression of coronary artery calcification and thoracic aorta calcification in kidney transplant recipients. Am J Kidney Dis 2012, 59:258-269.
81. Block G.A., Klassen P.S., Lazarus J.M., Ofsthun N., Lowrie E.G., Chertow G.M. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004, 15:2208-2218.
82. Kestenbaum B., Sampson J.N., Rudser K.D., Patterson D.J., Seliger S.L., Young B., et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005, 16:520-528.
83. Ganesh S.K., Stack A.G., Levin N.W., Hulbert-Shearon T., Port F.K. Association of elevated serum PO4, Ca PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001, 12:2131-2138.
84. Tentori F., Blayney M.J., Albert J.M., Gillespie B.W., Kerr P.G., Bommer J., et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008, 52:519-530.
85. Wolf M., Molnar M.Z., Amaral A.P., Czira M.E., Rudas A., Ujszaszi A., et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011, 22:956-966.
86. Nguyen P.T., Henrard S., Coche E., Goffin E., Devuyst O., Jadoul M. Coronary artery calcification: a strong predictor of cardiovascular events in renal transplant recipients. Nephrol Dial Transplant 2010, 25:3773-3778.
87. DeLoach S.S., Joffe M.M., Mai X., Goral S., Rosas S.E. Aortic calcification predicts cardiovascular events and all-cause mortality in renal transplantation. Nephrol Dial Transplant 2009, 24:1314-1319.
88. Schwarz S., Trivedi B.K., Kalantar-Zadeh K., Kovesdy C.P. Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol 2006, 1:825-831.
89. Noordzij M., Voormolen N.M.C., Boeschoten E.W., Dekker F.W., Bos W.J., Krediet R.T., et al. Disordered mineral metabolism is not a risk factor for loss of residual renal function in dialysis patients. Nephrol Dial Transplant 2009, 24:1580-1587. NECOSAD Study Group.
90. Egbuna O., Taylor J., Buchinsky D., Zand M. Elevated calcium phosphate product after renal transplantation is a risk factor for graft failure. Clin Transplant 2007, 21:558-566.
91. Schaeffner E.S., Födinger M., Kramar R., Sunder-Plassmann G., Winkelmayer C. Prognostic associations of serum calcium, phosphate and calcium phosphate concentration product with outcomes in kidney transplant recipients. Transpl Int 2007, 20:247-255.
92. Connolly G.M., Cunningham R., McNamee P.T., Young I.S., Maxwell A.P. Elevated serum phosphate predicts mortality in renal transplant recipients. Transplantation 2009, 87:1040-1044.
93. Evenepoel P., Lerut E., Naesens M., Bammens B., Claes K., Kuypers D., et al. Localization, etiology and impact of calcium phosphate deposits in renal allografts. Am J Transplant 2009, 9:2470-2478.
94. Schwarz A., Mengel M., Gwinner W., Radermacher J., Hiss M., Kreipe H., et al. Risk factors for chronic allograft nephropathy after renal transplantation: a protocol biopsy study. Kidney Int 2005, 67:341-348.
95. Nikkel L.E., Hollenbeak C.S., Fox E.J., Uemura T., Ghahramani N. Risk of fractures after renal transplantation in the United States. Transplantation 2009, 87:1846-1851.
96. Nisbeth U., Lindh E., Ljunghall S., Backman U., Fellstrom B. Increased fracture rate in diabetes mellitus and females after renal transplantation. Transplantation 1999, 67:1218-1222.
97. O'Shaughnessy E.A., Dahl D.C., Smith C.L., Kasiske B.L. Risk factors for fractures in kidney transplantation. Transplantation 2002, 74:362-366.
98. Vautour L.M., Melton L.J., Clarke B.L., Achenbach S.J., Oberg A.L., McCarthy J.T. Long-term fracture risk following renal transplantation: a population-based study. Osteoporos Int 2004, 15:160-167.
99. Abbott K.C., Oglesby R.J., Hypolite I.O., Kirk A.D., Ko C.W., Welch P.G., et al. Hospitalizations for fractures after renal transplantation in the United States. Ann Epidemiol 2001, 11:450-457.
100. Palmer S.C., Strippoli G.F.M., McGregor D.O. Interventions for preventing bone disease in kidney transplant recipients. Am J Kidney Dis 2005, 45:638-649.
101. Ball A.M., Gillen D.L., Sherrard D., Weiss N.S., Emerson S.S., Seliger S.L., et al. Risk of hip fracture among dialysis and renal transplant recipients. JAMA 2002, 288:3014-3018.
102. Ghanekar H., Welch B.J., Moe O.W., Sakhaee K. Post-renal transplantation hypophosphatemia: a review and novel insights. Curr Opin Nephrol Hypertens 2006, 15:97-104.
103. Durieux S., Mercadal L., Orcel P., Dao H., Rioux C., Bernard M., et al. Bone mineral density and fracture prevalence in long-term kidney graft recipients. Transplantation 2002, 74:496-500.
104. Nickolas T.L., Leonard M.B., Shane E. Chronic kidney disease and bone fracture: a growing concern. Kidney Int 2008, 74:721-731.
105. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009, 113:S1-S130. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group.
106. Weisinger J.R., Carlini R.G., Rojas E., Bellorin-Font E. Bone disease after renal transplantation. Clin J Am Soc Nephrol 2006, 1:1300-1313.
107. Lieben L., Carmeliet G., Masuyama R. Calcemic actions of vitamin D: effects on the intestine, kidney and bone. Best Pract Res Clin Endocrinol Metab 2011, 25:561-572.
108. Quesada Gomez J.M., Blanch R.J., Diaz C.M., Diez P.A. Calcium citrate and vitamin D in the treatment of osteoporosis. Clin Drug Investig 2011, 31:285-298.
109. Haas M., Leko-Mohr Z., Roschger P., Kletzmayr J., Schwarz C., Mitterbauer C., et al. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int 2003, 63:1130-1136.
110. Weber T.J., Quarles L.D. Preventing bone loss after renal transplantation with bisphosphonates: we can. but should we?. Kidney Int 2000, 57:735-737.
111. Miller P.D. The kidney and bisphosphonates. Bone 2011, 49:77-81.
112. Mathieu C., Jafari M. Immunomodulation by 1,25-dihydroxyvitamin D3: therapeutic implications in hemodialysis and renal transplantation. Clin Nephrol 2006, 66:275-283.
113. O'Herrin J.K., Hullett D.A., Heisey D.M., Sollinger H.W., Becker B.N. A retrospective evaluation of 1,25-dihydroxyvitamin D(3) and its potential effects on renal allograft function. Am J Nephrol 2002, 22:515-520.
114. Toussaint N.D., Lau K.K., Strauss B.J., Polkinghorne K.R., Kerr P.G. Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis 2010, 56:57-68.
115. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
116. Cummings S.R., San M.J., McClung M.R., Siris E.S., Eastell R., Reid I.R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009, 361:756-765.
117. Jamal S.A., Ljunggren O., Stehman-Breen C., Cummings S.R., McClung M.R., Goemaere S., et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 2011, 26:1829-1835.
118. Leibbrandt A., Penninger J.M. TNF conference 2009: beyond bones-RANKL/RANK in the immune system. Adv Exp Med Biol 2011, 691:5-22.
119. Evenepoel P., Claes K., Kuypers D.R., Debruyne F., Vanrenterghem Y. Parathyroidectomy after successful kidney transplantation: a single centre study. Nephrol Dial Transplant 2007, 22:1730-1737.
120. Collaud S., Staub-Zahner T., Trombetti A., Clerici T., Marangon N., Binet I., et al. Increase in bone mineral density after successful parathyroidectomy for tertiary hyperparathyroidism after renal transplantation. World J Surg 2008, 32:1795-1801.
121. Milas M., Weber C.J. Near-total parathyroidectomy is beneficial for patients with secondary and tertiary hyperparathyroidism. Surgery 2004, 136:1252-1260.
122. Abdelhadi M., Nordenstrom J. Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism. J Clin Endocrinol Metab 1998, 83:3845-3851.
123. Evenepoel P., Claes K., Kuypers D., Maes B., Vanrenterghem Y. Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: a single centre study. Nephrol Dial Transplant 2005, 20:1714-1720.
124. Schwarz A., Rustien G., Merkel S., Radermacher J., Haller H. Decreased renal transplant function after parathyroidectomy. Nephrol Dial Transplant 2007, 22:584-591.
125. Kandil E., Florman S., Alabbas H., Abdullah O., McGee J., Noureldine S., et al. Exploring the effect of parathyroidectomy for tertiary hyperparathyroidism after kidney transplantation. Am J Med Sci 2010, 339:420-424.
126. Morales E., Gutierrez E., Andres A. Treatment with calcimimetics in kidney transplantation. Transplant Rev (Orlando) 2010, 24:79-88.
127. Bergua C., Torregrosa J.V., Fuster D., Gutierrez-Dalmau A., Oppenheimer F., Campistol J.M. Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism. Transplantation 2008, 86:413-417.
128. Borchhardt K.A., Diarra D., Sulzbacher I., Benesch T., Haas M., Sunder-Plassmann G. Cinacalcet decreases bone formation rate in hypercalcemic hyperparathyroidism after kidney transplantation. Am J Nephrol 2010, 31:482-489.
129. Schwarz A., Merkel S., Leitolf H., Haller H. The effect of cinacalcet on bone remodeling and renal function in transplant patients with persistent hyperparathyroidism. Transplantation 2011, 91:560-565.
130. Evenepoel P. Calcimimetics in chronic kidney disease: evidence, opportunities and challenges. Kidney Int 2008, 74:265-275.
131. Saag K.G., Shane E., Boonen S., Marin F., Donley D.W., Taylor K.A., et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007, 357:2028-2039.
132. Cejka D., Benesch T., Krestan C., Roschger P., Klaushofer K., Pietschmann P., et al. Effect of teriparatide on early bone loss after kidney transplantation. Am J Transplant 2008, 8:1864-1870.
133. Padhi D., Jang G., Stouch B., Fang L., Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011, 26:19-26.
134. Ambühl P.M., Meier D., Wolf B., Dydak U., Boesiger P., Binswanger U. Metabolic aspects of phosphate replacement therapy for hypophosphatemia after renal transplantation: impact on muscular phosphate content, mineral metabolism, and acid/base homeostasis. Am J Kidney Dis 1999, 34:875-883.
135. Caravaca F., Fernandez M., Ruiz-Calero R., Cubero J., Aparicio A., Jimenez F., et al. Effects of oral phosphorus supplementation on mineral metabolism of renal transplant recipients. Nephrol Dial Transplant 1998, 13:2605-2611.
136. Riella L.V., Rennke H.G., Grafals M., Chandraker A. Hypophosphatemia in kidney transplant recipients: report of acute phosphate nephropathy as a complication of therapy. Am J Kidney Dis 2011, 57:641-645.
137. Poesen R., Dierickx D., Evenepoel P. Hemolytic anemia associated with severe hypophosphatemia in a renal transplant recipient. Transpl Int 2012, 25:e27-e28.